Compare · AMGN vs VCEL
AMGN vs VCEL
Side-by-side comparison of Amgen Inc. (AMGN) and Vericel Corporation (VCEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and VCEL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $177.16B, about 100.7x VCEL ($1.76B).
- Over the past year, AMGN is up 16.8% and VCEL is down 16.5% - AMGN leads by 33.3 points.
- AMGN has been more active in the news (36 items in the past 4 weeks vs 4 for VCEL).
- AMGN has more recent analyst coverage (25 ratings vs 11 for VCEL).
- Company
- Amgen Inc.
- Vericel Corporation
- Price
- $338.27+3.07%
- $34.72+0.84%
- Market cap
- $177.16B
- $1.76B
- 1M return
- +4.47%
- -4.80%
- 1Y return
- +16.80%
- -16.46%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- News (4w)
- 36
- 4
- Recent ratings
- 25
- 11
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Latest AMGN
- AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- Ember LifeSciences announces new strategic investments boosting Series A to $27M
- Director Miles Amy E was granted 665 shares, increasing direct ownership by 13% to 5,640 units (SEC Form 4)
- Director Kullman Ellen Jamison was granted 665 shares, increasing direct ownership by 5% to 14,536 units (SEC Form 4)
- Director Klotman Mary E. was granted 665 shares, increasing direct ownership by 43% to 2,211 units (SEC Form 4)
- Director Jacks Tyler was granted 665 shares, increasing direct ownership by 4% to 18,284 units (SEC Form 4)
- Director Ishrak Omar was granted 665 shares, increasing direct ownership by 10% to 7,359 units (SEC Form 4)
- Director Holley Charles M was granted 665 shares, increasing direct ownership by 5% to 12,799 units (SEC Form 4)
- Director Garland Greg C. was granted 665 shares, increasing direct ownership by 5% to 13,848 units (SEC Form 4)
Latest VCEL
- The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
- Vericel Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Director Mclaughlin Kevin F exercised 7,000 shares at a strike of $7.84 and sold $229,775 worth of shares (7,000 units at $32.83) as part of a pre-agreed trading plan (SEC Form 4)
- Director Wotton Paul K sold $327,425 worth of shares (10,000 units at $32.74), decreasing direct ownership by 35% to 18,802 units (SEC Form 4)
- Chief Financial Officer Mara Joseph Anthony Jr sold $202,500 worth of shares (5,000 units at $40.50) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 21,009 units (SEC Form 4)
- Principal Accounting Officer Siegal Jonathan sold $188,045 worth of shares (4,855 units at $38.73) as part of a pre-agreed trading plan, decreasing direct ownership by 81% to 1,118 units (SEC Form 4)
- SEC Form 10-Q filed by Vericel Corporation
- Vericel Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
- Director Wotton Paul K converted options into 3,200 shares, increasing direct ownership by 12% to 28,802 units (SEC Form 4)